SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Integra LifeSciences Holdings Corporation (IART) News

Follow Integra LifeSciences Holdings Corporation (IART) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 33 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol IART Asset equity Sector Markets 90 days 24 Last 13.99 Updated Oct 23, 2026, 08:11 PM UTC Open live news feed Open IART chart & news
M Integra LifeSciences Reports Third-Quarter 2026 Revenue of $411.18 Million Net income was $14.85 million and diluted EPS was $0.19, compared with a $5.4 million net loss and a $0.07 per-share loss a year earlier. Revenue was $402.06 million in the prior-year quarter. EQUITY | Oct 23, 2026, 08:11 PM UTC M Integra LifeSciences Reports Quarterly Results Integra LifeSciences reported results for the quarter ended September 30. The supplied text contains no financial figures. EQUITY | Oct 21, 2026, 01:31 PM UTC M Integra LifeSciences Reports Third-Quarter Revenue of $411.2M EQUITY | Oct 21, 2026, 10:23 AM UTC M Integra LifeSciences Q3 Revenue Slightly Misses Estimates on Flood Damage EQUITY | Oct 21, 2026, 10:10 AM UTC M Integra LifeSciences Sees Fourth-Quarter Revenue at $413M-$433M EARNINGS | Oct 21, 2026, 10:02 AM UTC M Integra LifeSciences Sees 2026 Adjusted EPS of $2.30-$2.40 EARNINGS | Oct 21, 2026, 10:02 AM UTC M Integra Lifesciences Affirms FY2026 EPS and Sales Guidance Integra affirmed FY2026 adjusted EPS guidance of $2.30–$2.40 and sales guidance of $1.634 billion–$1.654 billion. The supplied estimates are $2.42 and $1.661 billion, respectively. EARNINGS | Oct 21, 2026, 10:01 AM UTC M Integra LifeSciences Sees 2026 Revenue at $1.63B-$1.65B EARNINGS | Oct 21, 2026, 10:01 AM UTC M Integra LifeSciences Q3 Adjusted EPS $0.59 vs. $0.56 Estimate Reuters reports Q3 EPS of $0.19. EARNINGS | Oct 21, 2026, 10:01 AM UTC L Integra LifeSciences reports third-quarter EPS EARNINGS | Oct 21, 2026, 10:00 AM UTC L Integra LifeSciences reports third-quarter net income of $14.9 million EARNINGS | Oct 21, 2026, 10:00 AM UTC M Integra LifeSciences to Host Q3 2026 Earnings Call Oct. 21 Integra LifeSciences Holdings Corporation will release its third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. The company will host a conference call to discuss the results. EQUITY | Oct 06, 2026, 12:33 PM UTC M Nasdaq Hits Fresh Highs as Dow Slips The Nasdaq Composite reached new record highs on Monday, while the Dow Jones Industrial Average experienced a decline, and small-cap stocks showed mixed direction. EQUITY | Oct 05, 2026, 06:29 PM UTC H Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook Integra LifeSciences Holdings Corporation (NASDAQ: IART ) shares plunged nearly 20% after the medical technology company on Friday reported preliminary third-quarter results and cut its full-year 2026 guidance. The stock LIVE | Oct 05, 2026, 05:44 PM UTC H Crude Oil Down Over 1%; US Factory Orders Edge Higher In August U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.45% to 51,157.95 while the NASDAQ jumped 1.27% to 27,212.06. The S&P 500 also rose, gaining, 0.79 LIVE | Oct 02, 2026, 05:08 PM UTC H Integra LifeSciences shares are trading lower after the company announced it anticipates that flooding will disrupt Q3 revenue. The company narrowed its FY26 adjusted EPS guidance and cut its FY26 revenue. Integra LifeSciences shares are trading lower after the company announced it anticipates that flooding will disrupt Q3 revenue. The company narrowed its FY26 adjusted EPS guidance and cut its FY26 revenue. LIVE | Oct 02, 2026, 01:02 PM UTC H Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. Bas LIVE | Oct 02, 2026, 12:09 PM UTC M Integra LifeSciences posts preliminary Q3 results, updates 2026 guidance Integra LifeSciences announced preliminary third-quarter results and updated full-year 2026 guidance. EQUITY | Oct 02, 2026, 12:05 PM UTC L Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patientsACCLARENT AERA® Eustachian Tube Balloon Dilation SystemPRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeScience NEWS | Sep 29, 2026, 12:32 PM UTC H Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026 Company to feature surgeon-led educational programming and technologies supporting liver surgeryCUSA MicroFrancePRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences NASDAQ:IART will mark 20 years of C GEOPOLITICS | Sep 25, 2026, 01:08 PM UTC L IART sees margin expansion and innovation support through 2027 EARNINGS | Sep 09, 2026, 07:54 PM UTC L Integra LifeSciences updates investor presentation on remediation progress Integra LifeSciences furnished an updated investor presentation covering remediation progress, Braintree facility start-up and LTM Q2 2026 financials. REGULATION | Sep 08, 2026, 10:34 AM UTC L Integra LifeSciences CFO and CCO to present at 2026 healthcare conferences Integra LifeSciences said Lea Knight (chief financial officer) and Michael McBreen (chief commercial officer) will present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference. EQUITY | Sep 04, 2026, 01:17 PM UTC L IART - Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference - Cli IART - Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference EQUITY | Sep 04, 2026, 01:15 PM UTC L IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV $418.8M vs. EST $418.6M, Integra Lifesciences Earnings Notes:, Integra Lifescien EARNINGS | Jul 29, 2026, 10:24 AM UTC L Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.65 Integra Lifesciences (NASDAQ: IART ) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 bill EARNINGS | Jul 29, 2026, 10:08 AM UTC L IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results EARNINGS | Jul 29, 2026, 10:00 AM UTC L IART new Neutral W/ $19 PT @ UBS IART new Neutral W/ $19 PT @ UBS EQUITY | Jul 28, 2026, 12:46 PM UTC L IART Initiated Neutral W/$19.00 PT at UBS IART Initiated Neutral W/$19.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S EQUITY | Jul 28, 2026, 11:11 AM UTC H BMO starts 'show-me story' Integra LifeSciences with a Market Perform As previously reported, BMO Capital initiated coverage of Integra LifeSciences with a Market Perform rating and $19 price target. While early signs of recovery - including a Q1 beat and record Integra Skin production - a EARNINGS | Jul 08, 2026, 08:34 PM UTC H Integra LifeSciences price target raised to $19 from $16 at Citi Citi raised the firm's price target on Integra LifeSciences to $19 from $16 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medt EQUITY | Jul 08, 2026, 10:36 AM UTC L IART Appoints Executives Integra LifeSciences announces key executive appointments to enhance commercial execution and customer engagement EQUITY | Jun 23, 2026, 12:01 PM UTC